- CFO Spotlights
- Profiles
- James Ahlers
Profile
James Ahlers
Chief Financial Officer, Cue Biopharma, Inc.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
James Ahlers has been Chief Financial Officer of Cue Biopharma, Inc. since July 30, 2026, according to the company's filing of August 3, 2026.1
The filing gives James Ahlers's previous role as consulting Chief Financial Officer and strategic advisor to emerging life sciences companies at Danforth Advisors, LLC.1 James Ahlers joined from outside Cue Biopharma, Inc., by the record's reading of the filing.1 The filing shows an earlier chief financial officer seat, so this is not James Ahlers's first.1
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Cue Biopharma, Inc. (CUE) Pharmaceutical Preparations | Chief Financial Officer | In the seat |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- July 30, 2026effective
Cue Biopharma, Inc. appointed James Ahlers as Chief Financial Officer, effective July 30, 2026.
On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).
[1] Filing by Cue Biopharma, Inc., filed with the SEC on August 3, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Cue Biopharma, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed August 3, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or James Ahlers wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.